How to Value a Corporate-Owned Veterinary Practice Being Divested

The veterinary roll-up story of 2015-2022 was one of the great M&A frenzies of the decade. Mars Petcare (via VCA and Banfield), JAB Holdings (via National Veterinary Associates), Thrive Pet Healthcare, PetVet Care Centers, and a dozen smaller aggregators paid 12-18x EBITDA for platform practices and 8-12x for bolt-ons. Then interest rates doubled, clinic visit volume normalized post-pandemic, and suddenly a lot of those deals looked very different on the balance sheet.

In 2026, I'm seeing something I haven't seen in a decade: corporate-owned vet practices coming back to market, often at a discount to what the consolidator paid for them. If you're looking at buying one, or you're a corporate divestiture team trying to price one, the valuation math is very different from a standard practice sale.

Why Corporate Practices Come Back to Market

There are three patterns I see repeatedly. First, portfolio rationalization — a consolidator decides a particular geography or clinic type no longer fits the strategy, and packages up 15-40 clinics for sale. Second, failed integration — the platform overpaid, couldn't retain the selling DVMs after their earn-outs expired, and watched production collapse. Third, lender-forced sales — the debt stack built during the zero-rate era no longer services, and the sponsor needs liquidity.

Each scenario produces different pricing dynamics. A rationalized portfolio divestiture is usually a clean process with reasonable data. A failed integration is a distressed asset that needs to be repriced based on current production, not historical. A lender-forced sale can create genuine bargains if you can move fast.

The Secondary Buyer Discount

Here's the uncomfortable truth corporate sellers don't want to hear: secondary buyers almost never pay what the original consolidator paid. The typical discount I see is 25-40% below the original purchase multiple, and there are structural reasons why.

When Mars or JAB bought a practice in 2019, they were paying for synergies they could extract across a 1,000-clinic platform: group purchasing on pharmaceuticals and supplies, centralized HR and accounting, lab testing markups through their own reference labs, and cross-referrals to owned specialty hospitals. A secondary buyer — usually a smaller regional group or a new PE-backed platform — can't access those synergies, so the economics don't support the same multiple.

A practice that originally sold at 14x EBITDA for $8.4M (on $600K EBITDA) in 2020 might change hands in 2026 at 8-9x EBITDA for $4.8M-$5.4M — and that's before you adjust for any production decline since the original sale. I've seen divestitures close at 7x when the selling DVM had already left and production was down 20%.

Repricing the EBITDA: What to Normalize

When you're underwriting a corporate-owned practice, the reported EBITDA is almost always unreliable. Corporate overhead allocations, management fees to the parent, and transfer pricing on lab work and pharmacy make the standalone P&L look very different than it will under new ownership.

Start by stripping out the management fee — typically 4-6% of revenue charged by the platform. That's usually added back, because most buyers will self-manage. Then look at the compensation structure. Corporate platforms pay DVMs on ProSal (production-based salary with a floor), and those comp ratios usually run 20-23% of personal production. If you're a private buyer planning to pay yourself as an owner-operator, your effective comp might drop to 18%, creating real margin expansion.

Next, examine lab and pharmacy margins. Corporate practices frequently run inflated COGS because they're buying from the parent company at internal transfer prices. I've seen practices where switching reference labs and opening a retail pharmacy account with MWI or Patterson adds 300-400 basis points of margin immediately.

Finally, look at staffing levels. Corporate practices often carry more support staff than an owner-operator would — extra CSRs, assistants, and sometimes a practice manager who could be eliminated. A realistic pro forma EBITDA is usually 10-25% higher than the reported number once you normalize these items, which protects some of your downside on the purchase.

Production Cliff Risk

The single biggest risk in buying a corporate-owned practice is what I call the "production cliff" — the steady decline that happens when the original selling DVM leaves after their earn-out expires and clinic goodwill erodes.

Pull the last 48 months of monthly production by provider. If the original selling DVM is still there, ask when their non-compete expires and what their current comp looks like versus their 2019 earnings. A DVM who used to own the practice and now earns 22% of production on a W-2 is often unhappy and flight-prone. Budget for the possibility they leave within 12 months of your acquisition.

If the original DVM has already left, the question is whether production has stabilized or is still declining. A practice that dropped from $2.4M to $1.9M in revenue but has been flat at $1.9M for the last 18 months is a very different asset than one still bleeding 2% per month. The former is a stabilized opportunity at 6-7x on the new run-rate; the latter is still catching a falling knife.

Valuation Benchmarks for Corporate Divestitures

Based on transactions I've seen close in 2024-2026, here's roughly where divested corporate vet practices are trading:

• Stabilized, DVM retained: 7-9x normalized EBITDA, typically $2.5M-$6M enterprise value for a single-location practice doing $1.5M-$3M in revenue.
• Stabilized, DVM departed: 5.5-7x normalized EBITDA on the current run-rate, not historical peak.
• Still declining production: 4-5.5x trailing EBITDA with heavy seller paper or earn-out components to bridge the valuation gap.
• Distressed / lender sale: 3.5-5x EBITDA or asset value, whichever is higher. I've seen equipment-and-lease deals close at book value plus a token for goodwill.

Compare these to a clean private-market practice sale, which is typically 6-9x EBITDA for a standard single-location general practice. The corporate discount is real but not catastrophic — the key is pricing the integration and retention risk honestly.

Red Flags in the CIM

When you receive the confidential information memorandum on a divested corporate practice, there are specific line items that should make you slow down. A sudden uptick in trailing-twelve-month revenue compared to the prior three years often reflects cherry-picked month ranges designed to inflate the sale price. Compare the TTM number to each of the three prior calendar years and ask for monthly revenue data so you can see the actual trajectory.

Large one-time "addbacks" for consulting fees, severance, or transition costs are another warning sign. Some of these are legitimate — a failed practice manager who was terminated 18 months ago is a real non-recurring expense. But a pattern of aggressive addbacks that lifts EBITDA by 25%+ from the reported number is usually a repricing tactic. Haircut every addback that isn't directly documented.

Finally, watch the provider headcount trend. A practice that was staffed with 4 DVMs in 2022 and is now running with 2.5 FTEs may be showing artificially strong per-DVM productivity metrics because the weakest providers left and their cases got redistributed. That productivity isn't sustainable without rehiring, and the rehire math eats into your projected margins.

Deal Structure Matters More Than Price

For corporate divestitures, I almost always push buyers toward structured deals rather than all-cash. A 70/30 cash-to-seller-note split with a 2-year earn-out tied to maintained production protects you from the production cliff scenario. If the platform is motivated to close, they'll usually accept it — their alternative is holding an underperforming asset on the balance sheet and taking an even bigger writedown at year-end.

Reps and warranties insurance is worth the cost on deals over $5M. Corporate sellers will push back hard on indemnification caps, and R&W insurance removes that friction from the negotiation while giving you real recourse if the financials turn out to be wrong.

The Bottom Line

Buying a corporate-owned vet practice coming out of a divestiture is one of the better risk-adjusted opportunities in the veterinary M&A market right now — but only if you price it as a secondary asset, not as a fresh practice sale. The original consolidators paid for synergies you can't access, overvalued goodwill that's partly eroded, and in many cases are now under pressure to sell. That's your opportunity, not theirs. Walk in with a normalized EBITDA model, a realistic view of retention risk, and a structured offer, and you can pick up quality practices at 5.5-7x — multiples we haven't seen in healthy veterinary practices since the mid-2010s.